drugset / Trial / NCT07414953
A Phase Ib Study of HS-10504 Combined Therapy in NSCLC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-10504 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2026-03-30
- Primary completion
- 2027-04-30
- Completion
- 2028-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-10504 | Unknown | — | Oral |
| Subject | HS-20117 | Monoclonal antibody | — | Intravenous |
| Subject | HS-20122 | Unknown | — | Intravenous |
| Subject | SHR-1826 | Unknown | — | Intravenous |
| Subject | SHR-A2009 | Other / unclassified | — | Intravenous |
| Subject | SHR-A2102 | Other / unclassified | — | Intravenous |